DERM (Journey Medical Corporation) stock: $4.47, $126.2M market cap, $25.6M cash, $121.0M EV, $143.6M fully diluted market cap. Data from Fully Diluted's biotech stocks database.
What they do
We are a commercial-stage pharmaceutical company that primarily focuses on the selling and marketing of U.S. Food and Drug Administration (“FDA”) approved prescription pharmaceutical products for the treatment of dermatological conditions. Our current product portfolio includes eight FDA-approved prescription drugs for dermatological conditions that are marketed in the U.S.
Partnerships Dr. Reddy's Laboratories: global rights (DRL retained select markets); $10M upfront, $3M NDA-acceptance milestone, $15M approval milestone; up to $150M contingent milestones; 10-14% royalties
Indications
Inflammatory lesions of rosacea in adults(Approved)
Status note FDA approved November 1, 2024 under 505(b)(2). Company also markets several other dermatology products (Amzeeq, Zilxi, Qbrexza, Accutane, Exelderm, Luxamend).
Dermatology (specific indication not stated)(Stage not disclosed)
Status note Development-stage dermatology program acquired from Vyne in January 2022; filing discloses no phase, indication, or development status beyond its acquisition.
Per-asset detail extracted from the 10-Q filed 2026-08-12. Fields the filing does not state are marked "not disclosed" rather than filled from other sources.
Sponsor-matched active trials from ClinicalTrials.gov (0 as sponsor, 1 as collaborator); "Sponsor" = company is the lead sponsor, "Collaborator" = company is a collaborator. The BP column flags big-pharma involvement as lead sponsor or collaborator (excluding the company itself). The Mgmt guide column shows what management guided for readout timing when a guided program matches the trial (hover for the quote, click for the source). Trial listings are not a company pipeline slide.